1Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, et.al
(2016) RRx-001, A novel dinitroazetidine radiosensitizer. Invest
New Drugs. 34:371-377.
2Ning S, Bednarski MD, Oronsky B, Scicinski J, Saul G,
et.al (2012) Dinitroazetidines are a novel class of anticancer
agents and hypoxia-activated radiation sensitizers developed
from highly energetic materials. Cancer Res. 72:2600-2608.
3Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, et.al
(2017) The immunomodulatory anticancer agent, RRx-001,
induces an interferon response through epigenetic induction
of viral mimicry. Clin Epigenetics. 19:9:4.
4Scicinski J, Oronsky B, Taylor M, Luo G, Musick T, et.al
(2012) Preclinical evaluation of the metabolism and disposition
of RRx-001, a novel investigative antic- ancer agent.
Drug Metab Dispos. 40:1810–1816.
5Reid T, Oronsky B, Scicinski J, et.al (2015) Safety and activity
of RRx-001 in patients with advanced cancer: a firstin-
human, open-label, dose- escalation phase 1 study. Lancet
Oncol. 16:1133-1142.
6Oronsky B, Reid TR, Larson C, Carter CA, Brzezniak CE,
et.al (2017) RRX-001 protects against cisplatin-induced toxicities.
J Cancer Res Clin Oncol. 143:1671-1677.
7Ning S, Sekar TV, Scicinski J, Oronsky B, Peehl DM, et.al
(2015) Nrf2 activity as a potential biomarker for the pan-epigenetic
anticancer agent, RRx-001. Oncotarget. 6-21547-
21556.